Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
María Molina‐Molina, Jessica Shull, Vanesa Vicens‐Zygmunt, Pilar Rivera‐Ortega, Katerina Antoniou, Francesco Bonella, Elisabetta Renzoni, Anne‐Marie Russell, Toby M. Maher, Ada Vancheri, Anna Bachs, Victoria Avilés, Josep Palma, Guadalupe Bermudo, Guillermo Suárez-Cuartín, Cristian Tebé, Raül Rigo‐Bonnin, Ana Montes‐Worboys, Marlies Wijsenbeek, Carlo Vancheri
Abstract
<h3>Tweetable abstract</h3> <b>Individuals with IPF who follow a MUFA diet report a lower incidence of pirfenidone gastrointestinal adverse events than those that follow a SFA diet, which could explain the different prevalence in GI pirfenidone AEs reported by countries in IPF cohorts</b>https://bit.ly/3LuzAUJ
Topics & Concepts
PirfenidoneIdiopathic pulmonary fibrosisMedicineAdverse effectIncidence (geometry)Internal medicineClinical trialGastroenterologyLungOpticsPhysicsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisRespiratory and Cough-Related ResearchDysphagia Assessment and Management